RALEIGH, N.C., Aug. 8 /PRNewswire/ -- LipoScience, Inc. today announced that it has entered into an agreement with ARUP Laboratories, a leading national clinical and anatomic pathology laboratory, to offer its proprietary NMR LipoProfile(R) test.
ARUP serves as the primary reference laboratory for more than half of the nation’s university teaching hospitals and children’s hospitals. Through the agreement with ARUP, these hospitals will now have access to the NMR LipoProfile test. ARUP’s other clients include multihospital groups, major commercial laboratories, group purchasing organizations, military and government facilities, and major clinics.
Studies show that 50 percent of the people who had heart attacks had normal cholesterol levels. Based on new research, we understand that heart disease, or blocking of the arteries is caused by lipoproteins. Lipoproteins are particles or containers in the blood that carry cholesterol.
“The NMR LipoProfile test is a tool that identifies patients at risk for heart disease that would normally be missed by traditional cholesterol tests alone and gives clinicians lipoprotein particle information to manage that risk appropriately,” stated Ronald L. Weiss, M.D., M.B.A., President and COO of ARUP Laboratories. Dr. Weiss added, “The NMR LipoProfile test is the only test that provides both the traditional cholesterol values and the number of lipoprotein particles. We are very pleased to add it to our comprehensive menu of testing services.”
“This agreement with ARUP is part of our strategy to make our technology available for broad use in clinical laboratories worldwide,” said Richard O. Brajer, President and CEO, LipoScience, Inc. Brajer added, “The weight of evidence supporting the number of low density lipoprotein particles (LDL-P) as a target of therapy continues to grow. More and more reference laboratories are recognizing the surge of momentum behind the NMR LipoProfile test.”
About LipoScience
Headquartered in Raleigh, N.C., LipoScience develops and markets new clinical applications of NMR spectroscopy in the areas of cardiovascular disease and metabolic disorders. Its flagship product, the NMR LipoProfile blood test, was introduced for clinical research in 1997 and for use in patient care in 1999.
Results previously reported from the Cardiovascular Health Study, Women’s Health Study, PLAC-1 and VA-HIT, among others, have all shown that numbers of atherogenic LDL particles to be more predictive of coronary heart disease events than LDL cholesterol. Further information is available at http://www.lipoprofile.com.
About ARUP
ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and an enterprise of the University of Utah and its Department of Pathology. With more than 1,800 employees, ARUP offers in excess of 2,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays, for patients throughout the country. Rather than competing with its clients for physician office business, ARUP chooses instead to support clients’ existing test menus by offering highly complex and unique tests, with accompanying consultative support, to enhance their abilities to provide local and regional laboratory services. ARUP’s clients include more than half of the nation’s university teaching hospitals and children’s hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology(TM). Further information about ARUP Laboratories can be found at http://www.aruplab.com.
LipoScience, Inc.
CONTACT: Michelle Turenne of LipoScience, Inc., +1-919-256-1306, ormturenne@liposcience.com; or Ronald L. Weiss, M.D., M.B.A., President andChief Operating Officer of ARUP Laboratories, +1-801-584-5188
